Sanofi to sell 50% of Opella in $17 billion deal with CD&R, job guarantees for France included
Sanofi, which is joining a growing number of drugmakers shedding consumer related businesses, said Opella had been valued at around 16 billion euros ($17 billion), or 14 times estimated core earnings (EBITDA) for 2024.
Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...
French drama over sovereign paracetamol is really about a deeper ailment: underinvestment.
Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...
Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential ...
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareSanofi and CD&R enter exclusive negotiations to transfer a 50% ...
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
The proposed sale turned into a real political issue because Opella's products include Doliprane, the best-selling medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback